Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 20, 2012

Chinese Organizations Ally on Biopharma

  • China’s Huya Bioscience International has teamed up with the country’s Tianjin Research Center of Basic Medical Sciences (TJRCBMS), to help exploit the commercial potential of new drug technologies emerging from TJRCBMS research. Headquartered in China and the U.S., Huya specializes in fostering the global co-development of biopharmaceuticals originating in China, and has established collaborations with Chinese the academic and industrial biopharma sectors to identify promising technologies and speed their development worldwide.

    TJRCBMS is a nonprofit biomedical research institution located at the Tianjin Medical University Campus. Creating ties with Huya will allow both organizations to collaborate on expediting the development of new drugs in China and worldwide. TJRCBMS will be able to consult with Huya’s team of drug development and globalization experts, and Huya will have first opportunity to evaluate R&D projects conducted at TJFCBMS and provide support. 



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »